CD274 and non-small cell lung carcinoma: Programmed death ligand‐1 (PD‐L1) is a therapeutic target, with immune checkpoint inhibitors (ICPIs) such as pembrolizumab and nivolumab currently being utilized for pretreated metastatic NSCLC and more recently in neoadjuvant protocols.6